{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:13:26Z","timestamp":1794539606814,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572200"],"award-info":[{"award-number":["81572200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772396"],"award-info":[{"award-number":["81772396"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial hyperplasia, pannus formation, and cartilage and bone destruction. Nuclear receptor subfamily 1 group D member 1 (NR1D1) functions as a transcriptional repressor and plays a vital role in inflammatory reactions. However, whether NR1D1 is involved in synovial inflammation and joint destruction during the pathogenesis of RA is unknown. In this study, we found that NR1D1 expression was increased in synovial tissues from patients with RA and decreased in RA Fibroblast-like synoviocytes (FLSs) stimulated with IL-1\u03b2 in vitro. We showed that NR1D1 activation decreased the expression of proinflammatory cytokines and matrix metalloproteinases (MMPs), while NR1D1 silencing exerted the opposite effect. Furthermore, NR1D1 activation reduced reactive oxygen species (ROS) generation and increased the production of nuclear transcription factor E2-related factor 2 (Nrf2)-associated enzymes. Mitogen-activated protein kinase (MAPK) and nuclear factor \u03baB (NF-\u03baB) pathways were blocked by the NR1D1 agonist SR9009 but activated by NR1D1 silencing. NR1D1 activation also inhibited M1 macrophage polarization and suppressed osteoclastogenesis and osteoclast-related genes expression. Treatment with NR1D1 agonist SR9009 in collagen-induced arthritis (CIA) mouse significantly suppressed the hyperplasia of synovial, infiltration of inflammatory cell and destruction of cartilage and bone. Our findings demonstrate an important role for NR1D1 in RA and suggest its therapeutic potential.<\/jats:p>","DOI":"10.1038\/s41419-020-2314-6","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T08:03:26Z","timestamp":1582013006000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["NR1D1 modulates synovial inflammation and bone destruction in rheumatoid arthritis"],"prefix":"10.1038","volume":"11","author":[{"given":"Hui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenghui","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuankun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"key":"2314_CR1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/ncprheum0047","volume":"1","author":"U Muller-Ladner","year":"2005","unstructured":"Muller-Ladner, U., Pap, T., Gay, R. E., Neidhart, M. & Gay, S. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. 1, 102\u2013110 (2005).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"2314_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrrheum.2015.157","volume":"12","author":"Z Szekanecz","year":"2016","unstructured":"Szekanecz, Z. & Koch, A. E. Successes and failures of chemokine-pathway targeting in rheumatoid arthritis. Nat. Rev. Rheumatol. 12, 5\u201313 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2314_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrrheum.2015.171","volume":"12","author":"IB McInnes","year":"2016","unstructured":"McInnes, I. B., Buckley, C. D. & Isaacs, J. D. Cytokines in rheumatoid arthritis\u2014shaping the immunological landscape. Nat. Rev. Rheumatol. 12, 63\u201368 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2314_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/ar2481","volume":"10","author":"SK Drexler","year":"2008","unstructured":"Drexler, S. K., Kong, P. L., Wales, J. & Foxwell, B. M. Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis. Arthritis Res. Ther. 10, 216 (2008).","journal-title":"Arthritis Res. Ther."},{"key":"2314_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrrheum.2012.190","volume":"9","author":"N Bottini","year":"2013","unstructured":"Bottini, N. & Firestein, G. S. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat. Rev. Rheumatol. 9, 24\u201333 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2314_CR6","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.40688","volume":"71","author":"K Hoshino-Negishi","year":"2019","unstructured":"Hoshino-Negishi, K. et al. Role of anti-fractalkine antibody in suppression of joint destruction by inhibiting migration of osteoclast precursors to the synovium in experimental arthritis. Arthritis Rheumatol. 71, 222\u2013231 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"2314_CR7","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/bph.12021","volume":"168","author":"SY Park","year":"2013","unstructured":"Park, S. Y. et al. Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis. Br. J. Pharmacol. 168, 1401\u20131411 (2013).","journal-title":"Br. J. Pharmacol."},{"key":"2314_CR8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.tips.2015.02.001","volume":"36","author":"MI Koenders","year":"2015","unstructured":"Koenders, M. I. & van den Berg, W. B. Novel therapeutic targets in rheumatoid arthritis. Trends Pharmacol. Sci. 36, 189\u2013195 (2015).","journal-title":"Trends Pharmacol. Sci."},{"key":"2314_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature11048","volume":"485","author":"H Cho","year":"2012","unstructured":"Cho, H. et al. Regulation of circadian behaviour and metabolism by REV-ERB-alpha and REV-ERB-beta. Nature 485, 123\u2013127 (2012).","journal-title":"Nature"},{"key":"2314_CR10","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.cell.2016.05.012","volume":"165","author":"X Zhao","year":"2016","unstructured":"Zhao, X. et al. Circadian amplitude regulation via FBXW7-targeted REV-ERBalpha degradation. Cell 165, 1644\u20131657 (2016).","journal-title":"Cell"},{"key":"2314_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1177\/0748730405277232","volume":"20","author":"F Guillaumond","year":"2005","unstructured":"Guillaumond, F., Dardente, H., Giguere, V. & Cermakian, N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J. Biol. Rhythms 20, 391\u2013403 (2005).","journal-title":"J. Biol. Rhythms"},{"key":"2314_CR12","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nm.3213","volume":"19","author":"E Woldt","year":"2013","unstructured":"Woldt, E. et al. Rev-erb-alpha modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat. Med. 19, 1039\u20131046 (2013).","journal-title":"Nat. Med."},{"key":"2314_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.febslet.2007.08.032","volume":"582","author":"H Duez","year":"2008","unstructured":"Duez, H. & Staels, B. Rev-erb alpha gives a time cue to metabolism. FEBS Lett. 582, 19\u201325 (2008).","journal-title":"FEBS Lett."},{"key":"2314_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature25170","volume":"553","author":"G Sulli","year":"2018","unstructured":"Sulli, G. et al. Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature 553, 351\u2013355 (2018).","journal-title":"Nature"},{"key":"2314_CR15","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nature12209","volume":"498","author":"MT Lam","year":"2013","unstructured":"Lam, M. T. et al. Rev-Erbs repress macrophage gene expression by inhibiting enhancer-directed transcription. Nature 498, 511\u2013515 (2013).","journal-title":"Nature"},{"key":"2314_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06568-5","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. REV-ERBalpha integrates colon clock with experimental colitis through regulation of NF-kappaB\/NLRP3 axis. Nat. Commun. 9, 4246 (2018).","journal-title":"Nat. Commun."},{"key":"2314_CR17","doi-asserted-by":"crossref","unstructured":"Griffin, P. et al. Circadian clock protein Rev-erbalpha regulates neuroinflammation. Proc. Natl Acad. Sci. USA 116, 5102\u20135107 (2019).","DOI":"10.1073\/pnas.1812405116"},{"key":"2314_CR18","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1016\/j.celrep.2018.11.101","volume":"25","author":"M Amir","year":"2018","unstructured":"Amir, M. et al. REV-ERBalpha regulates TH17 cell development and autoimmunity. Cell Rep. 25, 3733\u20133749 (2018).","journal-title":"Cell Rep."},{"key":"2314_CR19","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1172\/JCI93910","volume":"128","author":"M Pariollaud","year":"2018","unstructured":"Pariollaud, M. et al. Circadian clock component REV-ERBalpha controls homeostatic regulation of pulmonary inflammation. J. Clin. Invest. 128, 2281\u20132296 (2018).","journal-title":"J. Clin. Invest."},{"key":"2314_CR20","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1053\/j.gastro.2017.12.019","volume":"154","author":"B Pourcet","year":"2018","unstructured":"Pourcet, B. et al. Nuclear receptor subfamily 1 group D member 1 regulates circadian activity of NLRP3 inflammasome to reduce the severity of fulminant hepatitis in mice. Gastroenterology 154, 1449\u20131464 (2018).","journal-title":"Gastroenterology"},{"issue":"23","key":"2314_CR21","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1111\/bph.14486","volume":"175","author":"Li-Jung Kang","year":"2018","unstructured":"Kang, L. J. et al. 3\u2032-Sialyllactose as an inhibitor of p65 phosphorylation ameliorates the progression of experimental rheumatoid arthritis. Br. J. Pharmacol. 175, 4295\u20134309 (2018).","journal-title":"British Journal of Pharmacology"},{"key":"2314_CR22","doi-asserted-by":"crossref","unstructured":"Clanchy, F. I. L. & Williams, R. O. Ibudilast inhibits chemokine expression in rheumatoid synovial fibroblasts and exhibits immunomodulatory activity in experimental arthritis. Arthritis Rheumatol. 71, 703\u2013711 (2018).","DOI":"10.1002\/art.40787"},{"key":"2314_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrrheum.2016.69","volume":"12","author":"U Fearon","year":"2016","unstructured":"Fearon, U., Canavan, M., Biniecka, M. & Veale, D. J. Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat. Rev. Rheumatol. 12, 385\u2013397 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2314_CR24","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1002\/art.22707","volume":"56","author":"Q Huang","year":"2007","unstructured":"Huang, Q., Ma, Y., Adebayo, A. & Pope, R. M. Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum. 56, 2192\u20132201 (2007).","journal-title":"Arthritis Rheum."},{"key":"2314_CR25","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.3389\/fimmu.2018.02228","volume":"9","author":"W Liu","year":"2018","unstructured":"Liu, W. et al. Sinomenine inhibits the progression of rheumatoid arthritis by regulating the secretion of inflammatory cytokines and monocyte\/macrophage subsets. Front. Immunol. 9, 2228 (2018).","journal-title":"Front. Immunol."},{"key":"2314_CR26","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/nrrheum.2009.55","volume":"5","author":"E Karouzakis","year":"2009","unstructured":"Karouzakis, E., Gay, R. E., Gay, S. & Neidhart, M. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat. Rev. Rheumatol. 5, 266\u2013272 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2314_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","volume":"233","author":"B Bartok","year":"2010","unstructured":"Bartok, B. & Firestein, G. S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol. Rev. 233, 233\u2013255 (2010).","journal-title":"Immunol. Rev."},{"key":"2314_CR28","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1016\/S0140-6736(17)31472-1","volume":"389","author":"IB McInnes","year":"2017","unstructured":"McInnes, I. B. & Schett, G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 389, 2328\u20132337 (2017).","journal-title":"Lancet"},{"key":"2314_CR29","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.autrev.2008.04.013","volume":"7","author":"HR Griffiths","year":"2008","unstructured":"Griffiths, H. R. Is the generation of neo-antigenic determinants by free radicals central to the development of autoimmune rheumatoid disease? Autoimmun. Rev. 7, 544\u2013549 (2008).","journal-title":"Autoimmun. Rev."},{"key":"2314_CR30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.bcp.2018.04.010","volume":"152","author":"ML Ferrandiz","year":"2018","unstructured":"Ferrandiz, M. L., Nacher-Juan, J. & Alcaraz, M. J. Nrf2 as a therapeutic target for rheumatic diseases. Biochem. Pharmacol. 152, 338\u2013346 (2018).","journal-title":"Biochem. Pharmacol."},{"key":"2314_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.freeradbiomed.2016.02.004","volume":"93","author":"S Sengupta","year":"2016","unstructured":"Sengupta, S. et al. The circadian gene Rev-erbalpha improves cellular bioenergetics and provides preconditioning for protection against oxidative stress. Free Radic. Biol. Med. 93, 177\u2013189 (2016).","journal-title":"Free Radic. Biol. Med."},{"key":"2314_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41401-018-0064-0","volume":"40","author":"DK Guo","year":"2019","unstructured":"Guo, D. K. et al. Pharmacological activation of REV-ERBalpha represses LPS-induced microglial activation through the NF-kappaB pathway. Acta Pharmacol. Sin. 40, 26\u201334 (2019).","journal-title":"Acta Pharmacol. Sin."},{"key":"2314_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189330","volume":"12","author":"EN Stujanna","year":"2017","unstructured":"Stujanna, E. N. et al. Rev-erb agonist improves adverse cardiac remodeling and survival in myocardial infarction through an anti-inflammatory mechanism. PLoS ONE 12, e0189330 (2017).","journal-title":"PLoS ONE"},{"key":"2314_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/art.1780390116","volume":"39","author":"D Mulherin","year":"1996","unstructured":"Mulherin, D., Fitzgerald, O. & Bresnihan, B. Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum. 39, 115\u2013124 (1996).","journal-title":"Arthritis Rheum."},{"key":"2314_CR35","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/ar86","volume":"2","author":"RW Kinne","year":"2000","unstructured":"Kinne, R. W., Br\u00e4uer, R., Stuhlm\u00fcller, B., Palombo-Kinne, E. & Burmester, G. R. Macrophages in rheumatoid arthritis. Arthritis Res. 2, 189\u2013202 (2000).","journal-title":"Arthritis Res."},{"key":"2314_CR36","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.ebiom.2019.04.058","volume":"43","author":"Y Luo","year":"2019","unstructured":"Luo, Y. et al. Human gingival tissue-derived MSC suppress osteoclastogenesis and bone erosion via CD39-adenosine signal pathway in autoimmune arthritis. EBioMedicine 43, 620\u2013631 (2019).","journal-title":"EBioMedicine"},{"key":"2314_CR37","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1096\/fj.201600825RRR","volume":"32","author":"C Song","year":"2018","unstructured":"Song, C. et al. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation. FASEB J. 32, 3215\u20133228 (2018).","journal-title":"FASEB J."},{"key":"2314_CR38","doi-asserted-by":"publisher","first-page":"12147","DOI":"10.1073\/pnas.1904226116","volume":"116","author":"P Dierickx","year":"2019","unstructured":"Dierickx, P. et al. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. Proc. Natl Acad. Sci. USA 116, 12147\u201312152 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2314_CR39","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1136\/ard.2010.148619","volume":"70","author":"K Britsemmer","year":"2011","unstructured":"Britsemmer, K., Ursum, J., Gerritsen, M., van Tuyl, L. H. & van Schaardenburg, D. Validation of the 2010 ACR\/EULAR classification criteria for rheumatoid arthritis: slight improvement over the 1987 ACR criteria. Ann. Rheum. Dis. 70, 1468\u20131470 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"2314_CR40","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/ard.2010.143560","volume":"70","author":"MZ Cader","year":"2011","unstructured":"Cader, M. Z. et al. Performance of the 2010 ACR\/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Ann. Rheum. Dis. 70, 949\u2013955 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"2314_CR41","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2, 1269\u20131275 (2007).","journal-title":"Nat. Protoc."},{"key":"2314_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001881","volume":"12","author":"JH Ryu","year":"2014","unstructured":"Ryu, J. H. et al. Hypoxia-inducible factor-2alpha is an essential catabolic regulator of inflammatory rheumatoid arthritis. PLoS Biol. 12, e1001881 (2014).","journal-title":"PLoS Biol."},{"key":"2314_CR43","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1136\/annrheumdis-2014-205779","volume":"74","author":"YP Zhao","year":"2015","unstructured":"Zhao, Y. P. et al. Progranulin protects against osteoarthritis through interacting with TNF-alpha and beta-Catenin signalling. Ann. Rheum. Dis. 74, 2244\u20132253 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"2314_CR44","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.7150\/thno.33376","volume":"9","author":"X Sun","year":"2019","unstructured":"Sun, X. et al. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention. Theranostics 9, 5183\u20135199 (2019).","journal-title":"Theranostics"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2314-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2314-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2314-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T09:45:28Z","timestamp":1670233528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2314-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["2314"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2314-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"28 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"129"}}